Impact of Nanofat grafting on healing outcomes in chronic non-healing wounds: A randomized, controlled study

Chronic non-healing wounds pose significant challenges in clinical care, leading to prolonged morbidity and substantial healthcare costs. Emerging therapies, such as nanofat grafting, have shown promise due to their regenerative potential. Nanofat is derived from adipose tissue and contains a high concentration of stromal vascular fraction (SVF) cells, including mesenchymal stem cells, which possess anti-inflammatory, angiogenic, and wound-healing properties.

This randomized controlled trial aims to evaluate the efficacy of nanofat grafting in improving healing outcomes for chronic non-healing wounds compared to standard wound care. The study includes patients with chronic wounds, such as diabetic foot ulcers and venous leg ulcers, who are randomized into two groups: one receiving nanofat grafting and the other receiving standard care alone. Key outcomes include wound closure rate, time to complete healing, reduction in wound size, pain scores, and improvement in quality of life.

Preliminary data suggests that nanofat grafting can accelerate wound healing by enhancing angiogenesis, reducing inflammation, and promoting tissue regeneration. This trial aims to provide robust evidence to support the integration of nanofat grafting into clinical practice for chronic wound management.